Financhill
Buy
51

GOVX Quote, Financials, Valuation and Earnings

Last price:
$2.33
Seasonality move :
-5.75%
Day range:
$2.15 - $2.28
52-week range:
$1.09 - $11.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.51x
Volume:
382K
Avg. volume:
1.6M
1-year change:
-58.72%
Market cap:
$21.3M
Revenue:
--
EPS (TTM):
-$9.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GOVX
Geovax Labs
$1.3M -- -- -- $14.60
AEMD
Aethlon Medical
-- -$0.20 -100% -85.16% --
CMRX
Chimerix
$312K -$0.24 7665% -35.71% --
EBS
Emergent BioSolutions
$297.5M $0.14 -4.04% -32.63% $12.00
SIGA
SIGA Technologies
-- -- -- -- --
TNXP
Tonix Pharmaceuticals Holding
$3.2M -$7.36 -15.32% -89.86% $5.83
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GOVX
Geovax Labs
$2.26 $14.60 $21.3M -- $0.00 0% --
AEMD
Aethlon Medical
$0.57 -- $8M -- $0.00 0% --
CMRX
Chimerix
$3.34 -- $300.4M -- $0.00 0% --
EBS
Emergent BioSolutions
$8.30 $12.00 $449.7M -- $0.00 0% 0.40x
SIGA
SIGA Technologies
$6.00 -- $428.4M 5.00x $0.60 0% 2.48x
TNXP
Tonix Pharmaceuticals Holding
$0.39 $5.83 $72M -- $0.00 0% 0.60x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GOVX
Geovax Labs
-- 5.640 -- 3.50x
AEMD
Aethlon Medical
-- 1.156 -- --
CMRX
Chimerix
-- 0.928 -- 6.13x
EBS
Emergent BioSolutions
56.58% 10.051 146.79% 1.18x
SIGA
SIGA Technologies
-- -0.139 -- 4.99x
TNXP
Tonix Pharmaceuticals Holding
9.72% 0.642 34.58% 2.52x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GOVX
Geovax Labs
-- -$5.9M -571.64% -575.49% -207.97% -$9.3M
AEMD
Aethlon Medical
-- -$2.9M -- -- -- -$2.2M
CMRX
Chimerix
-- -$24.8M -48.21% -48.22% -95357.69% -$20.5M
EBS
Emergent BioSolutions
$161.2M $64.5M -14.79% -35.94% 53.1% $147.9M
SIGA
SIGA Technologies
$5.4M $542.1K 52.07% 52.07% 5.42% -$7.4M
TNXP
Tonix Pharmaceuticals Holding
$1.3M -$13.9M -139.38% -150.01% -492.06% -$18.8M

Geovax Labs vs. Competitors

  • Which has Higher Returns GOVX or AEMD?

    Aethlon Medical has a net margin of -208.48% compared to Geovax Labs's net margin of --. Geovax Labs's return on equity of -575.49% beat Aethlon Medical's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GOVX
    Geovax Labs
    -- -$0.91 $8.5M
    AEMD
    Aethlon Medical
    -- -$0.20 --
  • What do Analysts Say About GOVX or AEMD?

    Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand Aethlon Medical has an analysts' consensus of -- which suggests that it could grow by 576.01%. Given that Aethlon Medical has higher upside potential than Geovax Labs, analysts believe Aethlon Medical is more attractive than Geovax Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    GOVX
    Geovax Labs
    3 0 0
    AEMD
    Aethlon Medical
    0 0 0
  • Is GOVX or AEMD More Risky?

    Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison Aethlon Medical has a beta of 1.792, suggesting its more volatile than the S&P 500 by 79.201%.

  • Which is a Better Dividend Stock GOVX or AEMD?

    Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aethlon Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geovax Labs pays -- of its earnings as a dividend. Aethlon Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GOVX or AEMD?

    Geovax Labs quarterly revenues are $2.8M, which are larger than Aethlon Medical quarterly revenues of --. Geovax Labs's net income of -$5.8M is lower than Aethlon Medical's net income of -$2.8M. Notably, Geovax Labs's price-to-earnings ratio is -- while Aethlon Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus -- for Aethlon Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GOVX
    Geovax Labs
    -- -- $2.8M -$5.8M
    AEMD
    Aethlon Medical
    -- -- -- -$2.8M
  • Which has Higher Returns GOVX or CMRX?

    Chimerix has a net margin of -208.48% compared to Geovax Labs's net margin of -87996.15%. Geovax Labs's return on equity of -575.49% beat Chimerix's return on equity of -48.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    GOVX
    Geovax Labs
    -- -$0.91 $8.5M
    CMRX
    Chimerix
    -- -$0.26 $135.8M
  • What do Analysts Say About GOVX or CMRX?

    Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand Chimerix has an analysts' consensus of -- which suggests that it could grow by 151.5%. Given that Geovax Labs has higher upside potential than Chimerix, analysts believe Geovax Labs is more attractive than Chimerix.

    Company Buy Ratings Hold Ratings Sell Ratings
    GOVX
    Geovax Labs
    3 0 0
    CMRX
    Chimerix
    5 0 0
  • Is GOVX or CMRX More Risky?

    Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison Chimerix has a beta of 1.018, suggesting its more volatile than the S&P 500 by 1.827%.

  • Which is a Better Dividend Stock GOVX or CMRX?

    Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geovax Labs pays -- of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GOVX or CMRX?

    Geovax Labs quarterly revenues are $2.8M, which are larger than Chimerix quarterly revenues of $26K. Geovax Labs's net income of -$5.8M is higher than Chimerix's net income of -$22.9M. Notably, Geovax Labs's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GOVX
    Geovax Labs
    -- -- $2.8M -$5.8M
    CMRX
    Chimerix
    -- -- $26K -$22.9M
  • Which has Higher Returns GOVX or EBS?

    Emergent BioSolutions has a net margin of -208.48% compared to Geovax Labs's net margin of 40.45%. Geovax Labs's return on equity of -575.49% beat Emergent BioSolutions's return on equity of -35.94%.

    Company Gross Margin Earnings Per Share Invested Capital
    GOVX
    Geovax Labs
    -- -$0.91 $8.5M
    EBS
    Emergent BioSolutions
    56.8% $2.06 $1.2B
  • What do Analysts Say About GOVX or EBS?

    Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand Emergent BioSolutions has an analysts' consensus of $12.00 which suggests that it could grow by 44.58%. Given that Geovax Labs has higher upside potential than Emergent BioSolutions, analysts believe Geovax Labs is more attractive than Emergent BioSolutions.

    Company Buy Ratings Hold Ratings Sell Ratings
    GOVX
    Geovax Labs
    3 0 0
    EBS
    Emergent BioSolutions
    1 0 0
  • Is GOVX or EBS More Risky?

    Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 1.594, suggesting its more volatile than the S&P 500 by 59.352%.

  • Which is a Better Dividend Stock GOVX or EBS?

    Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geovax Labs pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GOVX or EBS?

    Geovax Labs quarterly revenues are $2.8M, which are smaller than Emergent BioSolutions quarterly revenues of $283.8M. Geovax Labs's net income of -$5.8M is lower than Emergent BioSolutions's net income of $114.8M. Notably, Geovax Labs's price-to-earnings ratio is -- while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus 0.40x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GOVX
    Geovax Labs
    -- -- $2.8M -$5.8M
    EBS
    Emergent BioSolutions
    0.40x -- $283.8M $114.8M
  • Which has Higher Returns GOVX or SIGA?

    SIGA Technologies has a net margin of -208.48% compared to Geovax Labs's net margin of 13.43%. Geovax Labs's return on equity of -575.49% beat SIGA Technologies's return on equity of 52.07%.

    Company Gross Margin Earnings Per Share Invested Capital
    GOVX
    Geovax Labs
    -- -$0.91 $8.5M
    SIGA
    SIGA Technologies
    53.59% $0.02 $169.4M
  • What do Analysts Say About GOVX or SIGA?

    Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand SIGA Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Geovax Labs has higher upside potential than SIGA Technologies, analysts believe Geovax Labs is more attractive than SIGA Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    GOVX
    Geovax Labs
    3 0 0
    SIGA
    SIGA Technologies
    0 0 0
  • Is GOVX or SIGA More Risky?

    Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison SIGA Technologies has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.87%.

  • Which is a Better Dividend Stock GOVX or SIGA?

    Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SIGA Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.60 per share. Geovax Labs pays -- of its earnings as a dividend. SIGA Technologies pays out 47.21% of its earnings as a dividend. SIGA Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GOVX or SIGA?

    Geovax Labs quarterly revenues are $2.8M, which are smaller than SIGA Technologies quarterly revenues of $10M. Geovax Labs's net income of -$5.8M is lower than SIGA Technologies's net income of $1.3M. Notably, Geovax Labs's price-to-earnings ratio is -- while SIGA Technologies's PE ratio is 5.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus 2.48x for SIGA Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GOVX
    Geovax Labs
    -- -- $2.8M -$5.8M
    SIGA
    SIGA Technologies
    2.48x 5.00x $10M $1.3M
  • Which has Higher Returns GOVX or TNXP?

    Tonix Pharmaceuticals Holding has a net margin of -208.48% compared to Geovax Labs's net margin of -503.65%. Geovax Labs's return on equity of -575.49% beat Tonix Pharmaceuticals Holding's return on equity of -150.01%.

    Company Gross Margin Earnings Per Share Invested Capital
    GOVX
    Geovax Labs
    -- -$0.91 $8.5M
    TNXP
    Tonix Pharmaceuticals Holding
    44.9% -$0.23 $82.2M
  • What do Analysts Say About GOVX or TNXP?

    Geovax Labs has a consensus price target of $14.60, signalling upside risk potential of 546.02%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $5.83 which suggests that it could grow by 1413.97%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Geovax Labs, analysts believe Tonix Pharmaceuticals Holding is more attractive than Geovax Labs.

    Company Buy Ratings Hold Ratings Sell Ratings
    GOVX
    Geovax Labs
    3 0 0
    TNXP
    Tonix Pharmaceuticals Holding
    2 0 0
  • Is GOVX or TNXP More Risky?

    Geovax Labs has a beta of 3.242, which suggesting that the stock is 224.241% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.232, suggesting its more volatile than the S&P 500 by 123.214%.

  • Which is a Better Dividend Stock GOVX or TNXP?

    Geovax Labs has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geovax Labs pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GOVX or TNXP?

    Geovax Labs quarterly revenues are $2.8M, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.8M. Geovax Labs's net income of -$5.8M is higher than Tonix Pharmaceuticals Holding's net income of -$14.2M. Notably, Geovax Labs's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geovax Labs is -- versus 0.60x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GOVX
    Geovax Labs
    -- -- $2.8M -$5.8M
    TNXP
    Tonix Pharmaceuticals Holding
    0.60x -- $2.8M -$14.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Is SoundHound AI Stock Up So Much?
Why Is SoundHound AI Stock Up So Much?

Like many companies improving AI technologies and exploring ways to…

Is The Santa Claus Rally The Gift That Keeps Giving?
Is The Santa Claus Rally The Gift That Keeps Giving?

Remember the horror of 2008 when the Great Recession hit…

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Buy
58
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
53
ARQQ alert for Dec 26

Arqit Quantum [ARQQ] is up 49.74% over the past day.

Buy
65
TSLL alert for Dec 26

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.62% over the past day.

Buy
75
SMLR alert for Dec 26

Semler Scientific [SMLR] is down 2.02% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock